Actively Recruiting

All Genders
NCT03409003

Orphan Europe Carbaglu® Surveillance Protocol

Led by Nicholas Ah Mew · Updated on 2024-02-07

30

Participants Needed

3

Research Sites

769 weeks

Total Duration

On this page

Sponsors

N

Nicholas Ah Mew

Lead Sponsor

B

Boston Children's Hospital

Collaborating Sponsor

AI-Summary

What this Trial Is About

The purpose of this study is to conduct post-marketing surveillance of carglumic acid (Carbaglu) to obtain long-term clinical safety information. Carglumic acid was approved by the United States Food and Drug Administration (FDA) for treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Much of the FDA-required data is already collected through the Longitudinal Study of Urea Cycle Disorders (RDCRN Protocol #5101). This study will collect additional data on adverse events (interim events), adverse reactions, pregnancy, and fetal outcomes.

CONDITIONS

Official Title

Orphan Europe Carbaglu® Surveillance Protocol

Who Can Participate

All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Confirmed diagnosis of NAGS deficiency or suspicion of NAGS deficiency
  • Carbaglu intake for the treatment of NAGS
  • Enrolled in the Longitudinal Study of Urea Cycle Disorders (RDCRN protocol #5101)
Not Eligible

You will not qualify if you...

  • Cases of hyperammonemia caused by other urea cycle disorders
  • Organic acidemia, lysinuric protein intolerance
  • Mitochondrial disorders
  • Congenital lactic acidemia
  • Fatty acid oxidation defects
  • Primary liver disease
  • Individuals with extreme low birth weight (<1,500 grams)

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 3 locations

1

Children's National Medical Center

Washington D.C., District of Columbia, United States, 20010

Actively Recruiting

2

Children's Hospital Boston (UCDC New England Center)

Boston, Massachusetts, United States, 02115

Actively Recruiting

3

Icahn School of Medicine at Mount Sinai

New York, New York, United States, 10029

Actively Recruiting

Loading map...

Research Team

J

Jennifer Seminara, MPH

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here